Screen failure data in clinical trials: Are screening logs worth it?

Author:

Elm Jordan J1,Palesch Yuko1,Easton J Donald23,Lindblad Anne4,Barsan William5,Silbergleit Robert5,Conwit Robin6,Dillon Catherine1,Farrant Mary23,Battenhouse Holly1,Perlmutter Aaron1,Johnston S Claiborne23

Affiliation:

1. Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC, USA

2. Department of Neurology, University of California, San Francisco, San Francisco, CA, USA

3. Department of Epidemiology & Biostatistics, University of California, San Francisco, San Francisco, CA, USA

4. The EMMES Corporation, Rockville, MD, USA

5. Department of Emergency Medicine, University of Michigan, Ann Arbor, MI, USA

6. National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA

Abstract

Background Clinical trials frequently spend considerable effort to collect data on patients who were assessed for eligibility but not enrolled. The Consolidated Standards of Reporting Trials (CONSORT) guidelines’ recommended flow diagram for randomized clinical trials reinforces the belief that the collection of screening data is a necessary and worthwhile endeavor. The rationale for collecting screening data includes scientific, trial management, and ethno-socio-cultural reasons. Purpose We posit that the cost of collecting screening data is not justified, in part due to inability to centrally monitor and verify the screening data in the same manner as other clinical trial data. Methods To illustrate the effort and site-to-site variability, we analyzed the screening data from a multicenter, randomized clinical trial of patients with transient ischemic attack or minor ischemic stroke (Platelet-Oriented Inhibition in New Transient Ischemic Attack and Minor Ischemic Stroke (POINT)). Results Data were collected on over 27,000 patients screened across 172 enrolling sites, 95% of whom were not enrolled. Although the rate of return of screen failure logs was high overall (95%), there were a considerable number of logs that were returned with ‘no data to report’ (23%), often due to administrative reasons rather than no patients screened. Conclusion In spite of attempts to standardize the collection of screening data, due to differences in site processes, multicenter clinical trials face challenges in collecting those data completely and uniformly. The efforts required to centrally collect high-quality data on an extensive number of screened patients may outweigh the scientific value of the data. Moreover, the lack of a standardized definition of ‘screened’ and the challenges of collecting meaningful characteristics for patients who have not signed consent limits the ability to compare across studies and to assess generalizability and selection bias as intended.

Publisher

SAGE Publications

Subject

Pharmacology,General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3